Thermo Fisher Scientific, a provider of science services, reported on Monday the receipt of US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its high-throughput, saliva based automated COVID-19 testing method, amplitude solution.

The FDA has approved the COVID-19 tests from saliva samples collected with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the amplitude solution. SDNA saliva collection devices are self-contained systems that provide sample consistency and long-term stability while protecting DNA and RNA transcripts post-collection to help ensure accurate test results with only two milliliters of saliva.

According to the company, the amplitude solution allows laboratories to increase COVID-19 PCR testing and process up to 8,000 samples in a single day. The system enables clinical labs to expand testing capacity with minimal hands-on time, equipment and staffing.

In addition, the amplitude solution's high-throughput capabilities can address testing needs for companies, schools, universities and communities to help them return to pre-pandemic life as well as designed to help labs detect SARS-CoV-2 variants.